Reference
Lewis PJ, et al. Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA). Lung Cancer 103 (Suppl. 1): S34 abstr. 71, Jan 2017 [abstract] - United Kingdom
Rights and permissions
About this article
Cite this article
Afatinib/erlotinib. Reactions Weekly 1694, 21 (2018). https://doi.org/10.1007/s40278-018-43423-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-43423-x